1448315-53-4

Basic information

• Product Name: 3-hydroxy-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide
• Synonyms: 3-hydroxy-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide
• CAS NO: 1448315-53-4
• Molecular Weight: 535.497
• Mol File: 1448315-53-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-hydroxy-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide(1448315-53-4)
• EPA Substance Registry System: 3-hydroxy-N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-5-(pentafluoro-λ⁶-sulphanyl)benzamide(1448315-53-4)

Safety Data

• Hazardous Substances Data: 1448315-53-4(Hazardous Substances Data)

Upstream product

• 1180675-98-2 3-bromo-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 833-96-5 3-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1180672-84-7 3-hydroxy-5-(pentafluoro-λ⁶-sulphanyl)benzoic acid 
• 1448317-23-4 4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]aniline 
• 1448317-22-3 1-(2-methyl-5-nitrophenyl)-6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazole 
• 1448317-21-2 1-(2,2-diethoxyethyl)-N-(2-methyl-5-nitrophenyl)-3-(pyridin-3-yl)-1H-pyrazole-5-amine 
• 222056-48-6 1-(2,2-diethoxyethyl)-3-(pyridin-3-yl)-1H-pyrazole-5-amine 
• 30510-18-0 nicotinoylacetonitrile 

Downstream Products

• 1448315-58-9 N-{4-methyl-3-[6-(pyridin-3-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(pentafluoro-λ⁶-sulphanyl)-5-(pyrrolidin-3-yloxy)benzamide 

Relevant articles and documents

Substituted phenylimidazopyrazoles and their use

The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.